Sort
46,585 grants matching “heart failure”
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
$665,332Alexander Egbe · Mayo Clinic Rochester · R01 · FY2025 · HL
Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children
$665,257Paul W. Burridge · Northwestern University At Chicago · R01 · FY2022 · CA
Randomized Controlled Trial of a Six-Month Mindfulness-Based Intervention for Type 2 Diabetes
$665,176Nazia T. Raja-Khan · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2020 · DK
Perinatal cardiomyocyte pruning driven by metabolic maturation: Opportunity for intervention
$665,169Sonnet Sky Jonker · Oregon Health & Science University · R01 · FY2020 · HL
Analyzing the Cardiac Power Grid: Adaptive responses to fluctuating local demand
$665,159James B Bassingthwaighte · University Of Washington · U01 · FY2016 · HL
Critical Sorting Steps and Pathways in the Trafficking of Cardiac Sarcoplasmic Reticulum Proteins
$665,129Zhenhui Chen · Indiana University Indianapolis · R01 · FY2023 · HL
3D Cine Magnetic Resonance Fingerprinting for Rapid Phenotyping of Cardiomyopathy
$665,121Imran Rashid · Case Western Reserve University · R01 · FY2023 · HL
Language Processing in Context Following Traumatic Brain Injury
$665,092Melissa C Duff · Vanderbilt University Medical Center · R01 · FY2022 · DC
Self-Regulation and Brain and Cognitive Health in Older Adults
$665,046Suzanne C Segerstrom · University Of Kentucky · R01 · FY2017 · AG
Myosin Movement in Vitro-Molecular Characterization
$665,027James A Spudich · Stanford University · R01 · FY2013 · GM
Enhancing the public health benefits of mammography screening by informing women of both breast cancer and breast arterial calcification results: A randomized trial to promote cardiovascular health
$665,018Guy H Montgomery · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA
Determining the genetic and social determinants of heart failure and mortality in patients with congenital heart disease
$664,944Andrew P. Landstrom · Duke University · R01 · FY2025 · HL
Endothelial glycocalyx reconstitution during sepsis
$664,880Eric Peter Schmidt · University Of Colorado Denver · R01 · FY2017 · HL
Mechanisms and Therapeutics for Congenital Aortic Valve Disease
$664,824Vidu Garg · Research Inst Nationwide Children'S Hosp · R01 · FY2024 · HL
Mechanisms and Therapeutics for Congenital Aortic Valve Disease
$664,824Vidu Garg · Research Inst Nationwide Children'S Hosp · R01 · FY2025 · HL
Preterm birth and long-term risk of cardiovascular disease in mothers and offspring
$664,798Casey Crump · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · HL
Preterm birth and long-term risk of cardiovascular disease in mothers and offspring
$664,798Casey Crump · Icahn School Of Medicine At Mount Sinai · R01 · FY2019 · HL
Preterm birth and long-term risk of cardiovascular disease in mothers and offspring
$664,798Casey Crump · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · HL
Ventricular arrhythmias and mechanisms of parasympathetic dysfunction following myocardial infarction
$664,777Marmar Vaseghi · University Of California Los Angeles · R01 · FY2024 · HL
A Digital Twin for Designing Bladder Treatment informed by Bladder Outlet Obstruction Mechanobiology (BOOM)
$664,706Anne Marie Robertson · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · DK
Activity Levels, Myosteatosis and Insulin Resistance/Diabetes Mellitus
$664,700Matthew A Allison · University Of California, San Diego · R01 · FY2023 · HL
Targeting the Arrhythmogenic Sources of Human Atrial Fibrillation
$664,678Vadim V Fedorov · Ohio State University · R01 · FY2018 · HL
Targeting the Arrhythmogenic Sources of Human Atrial Fibrillation
$664,678Vadim V Fedorov · Ohio State University · R01 · FY2020 · HL
Targeting the Arrhythmogenic Sources of Human Atrial Fibrillation
$664,678Vadim V Fedorov · Ohio State University · R01 · FY2019 · HL
ADULT HUMAN PROGENITOR CELLS FOR CARDIAC REGENERATION
$664,605Richard P Schwarz · Kardia Therapeutics, Inc. · R42 · FY2008 · HL